Luspatercept Approval Status
FDA Approved: No (Pending Approval)
Generic name: luspatercept
Company: Celgene Corporation
Luspatercept is a first-in-class erythroid maturation agent (EMA) in development for the treatment of myelodysplastic syndromes (MDS)-associated anemia and beta-thalassemia-associated anemia.
Development Status and FDA Approval Process for luspatercept
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.